What you need to know
- Autoimmune diseases happen when the immune system mistakenly attacks the body’s own tissues. Treatment combines medications that calm the immune system with lifestyle changes that reduce inflammation and support overall health.
- For rheumatoid arthritis — one of the most common autoimmune conditions — modern treatment relies on disease-modifying antirheumatic drugs (DMARDs), starting with methotrexate and stepping up to biologic and targeted therapies as needed.
- Lifestyle factors meaningfully influence both the development and the course of autoimmune disease. Quitting smoking, maintaining a healthy weight, regular movement, and an anti-inflammatory diet all support better outcomes.
Autoimmune disease is the umbrella term for a large group of conditions in which the immune system, which normally targets infections and other threats, mistakenly attacks the body’s own tissues. The result is chronic inflammation in the affected organs — joints in rheumatoid arthritis, the thyroid in Hashimoto’s disease, the gut in inflammatory bowel disease, the nervous system in multiple sclerosis, the skin in psoriasis, and so on. There are more than 80 recognized autoimmune diseases, and they share more in common in their treatment than the variety of names might suggest.
This article uses rheumatoid arthritis (RA) as the main example because it is one of the most common, most studied, and most clearly illustrative of how modern autoimmune disease management works. Many of the same medication classes and lifestyle principles apply, with adjustments, across other autoimmune conditions.
Lifestyle factors meaningfully influence both the development and the course of autoimmune disease.
What rheumatoid arthritis is
Rheumatoid arthritis is a chronic autoimmune disease that primarily affects joints, causing pain, swelling, stiffness, and loss of function. Symptoms typically affect the same joints on both sides of the body — most often the hands, wrists, and feet to start — and morning stiffness lasting more than 30 minutes is a hallmark. Persistent fatigue and a general sense of being unwell are also common.
RA is more than a joint disease. The same systemic inflammation can affect the lungs, eyes, skin, and blood vessels, and is associated with higher cardiovascular risk over the long term. The fatigue that comes with active RA is often more disabling than the joint pain itself, and is one of the reasons treating the underlying disease — not just the symptoms — matters. If you are working through general unexplained tiredness, autoimmune disease is one of the categories worth considering when other common causes have been ruled out.
The current treatment philosophy in RA is called “treat to target.” The aim is to push disease activity down to remission or low activity, then keep it there. Most joint damage in RA happens within the first months to years if treatment is delayed, so starting therapy early and adjusting it aggressively when control is incomplete is central to modern care.
The medication ladder
Treatment is built in layers. Symptom-relief medications calm pain and inflammation in the short term. Disease-modifying medications change the underlying course of the illness over weeks to months.
Symptom relief: NSAIDs and corticosteroids
NSAIDs (ibuprofen, naproxen, celecoxib, and others) reduce pain and inflammation but do not slow joint damage and are not used as the long-term backbone of treatment. They are typically used for short-term symptom relief while a disease-modifying treatment takes effect.
Corticosteroids (prednisone is the most common oral form) are powerful anti-inflammatories useful for flares and as a short-term bridge while DMARDs are starting to work. Long-term oral steroid use causes meaningful side effects — weight gain, bone loss, blood sugar elevation, increased infection risk, mood changes, cataracts — so the principle is “lowest dose, shortest duration.” Joint injections of corticosteroid can target a single problem joint without the whole-body exposure.
Conventional DMARDs (csDMARDs)
These are the workhorses of long-term RA treatment. Methotrexate is the anchor drug, recommended as the first DMARD for most people with RA unless there is a specific reason not to use it. It is taken once a week, either by mouth or as a self-injection, and is paired with daily folic acid to reduce side effects. Most people see meaningful improvement over 6 to 12 weeks.
Other conventional DMARDs include hydroxychloroquine (originally developed as an antimalarial, now widely used for milder RA and for lupus), sulfasalazine, and leflunomide. They are sometimes used alone for milder disease and sometimes combined with methotrexate for additive effect. All require periodic blood tests to check liver function, blood counts, and kidney function.
Biologic DMARDs
Biologics are protein-based medications that target specific parts of the immune system. They are typically added when methotrexate alone is not enough to bring disease activity under control. Most are given by injection or infusion. Major classes include:
- TNF inhibitors — adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), golimumab (Simponi), certolizumab pegol (Cimzia). Often the first biologic tried, with the largest body of evidence and a long track record.
- IL-6 inhibitors — tocilizumab (Actemra), sarilumab (Kevzara). Particularly useful when TNF inhibitors are not effective or not tolerated.
- B-cell depletion — rituximab (Rituxan). Used in seropositive RA when other biologics have not worked.
- T-cell co-stimulation modulator — abatacept (Orencia).
All biologics calm the immune system and therefore raise the risk of certain infections. Tuberculosis screening, hepatitis B testing, and assessment of vaccination status are routine before starting. Live vaccines should be given before starting (or with a planned pause), not while on therapy. Most other vaccines remain effective and important.
All biologics calm the immune system and therefore raise the risk of certain infections.
Targeted synthetic DMARDs (JAK inhibitors)
Tofacitinib (Xeljanz), baricitinib (Olumiant), and upadacitinib (Rinvoq) are oral medications that block enzymes inside immune cells called Janus kinases. They are highly effective and convenient — pills, not injections — but more recent safety data have prompted regulators to recommend them generally after biologics rather than instead of them, particularly in people aged 65 and over, current or former smokers, and those with cardiovascular or cancer risk factors. Discussing the personal benefit-risk balance with a rheumatologist is important.
Lifestyle support
Lifestyle changes do not replace DMARDs, but they make medications work better and improve overall outcomes — including the cardiovascular risk that comes with long-term inflammation.
Quit smoking. This is the most evidence-backed lifestyle change in RA. Smoking increases the risk of developing RA, makes existing disease more severe, and reduces how well DMARDs work. Quitting at any stage helps.
Maintain a healthy weight. Obesity is associated with more severe RA, poorer treatment response, and added stress on weight-bearing joints. Even modest weight loss in people who are overweight or obese improves both pain and treatment effectiveness.
Eat an anti-inflammatory pattern. The Mediterranean dietary pattern — rich in vegetables, fruit, whole grains, legumes, fish, nuts, and olive oil, with limited red and processed meat — has the strongest evidence in autoimmune and inflammatory conditions. It is associated with lower disease activity and better cardiovascular outcomes, which matters in RA because heart disease risk is elevated. Restrictive elimination diets popularized online (carnivore, autoimmune protocol, very low-carb) are not supported by good evidence and can cause nutritional gaps.
Stay active. Regular movement reduces joint stiffness, supports muscle around inflamed joints, and improves fatigue and mood. The combination that works best is a mix of low-impact aerobic activity (walking, swimming, cycling), strength training, and flexibility work. A physical therapist familiar with rheumatic conditions can help build a starting routine that respects flares without de-conditioning.
Sleep and stress. Poor sleep and chronic stress both raise systemic inflammation and worsen pain perception. How stress shows up in the body is particularly relevant in autoimmune disease, because flares often correlate with stressful life events. Cognitive behavioral therapy for chronic pain, mindfulness-based stress reduction, and consistent sleep schedules all have evidence behind them.
Routine vaccinations and dental care. Periodontal disease appears to interact with autoimmunity in RA specifically, and good dental hygiene with regular cleanings is more than cosmetic. Most non-live vaccines (flu, pneumococcal, COVID-19, RSV, Tdap, shingles) are recommended and remain effective on most autoimmune therapies.
A note on other autoimmune conditions
The medication framework above — symptom relief, conventional DMARDs, biologics, and targeted synthetic DMARDs — applies in adapted forms across many autoimmune diseases. Lupus uses many of the same drugs (hydroxychloroquine is foundational; biologics like belimumab are added in some cases). Psoriasis and psoriatic arthritis use the same biologic classes plus IL-17 and IL-23 inhibitors specific to the skin pathway. Inflammatory bowel disease uses TNF inhibitors, IL-12/23 inhibitors, and integrin inhibitors. Multiple sclerosis has its own family of disease-modifying therapies.
What is consistent is the philosophy: identify the disease as early as possible, treat it actively rather than just managing symptoms, and pair medications with lifestyle changes that reduce systemic inflammation and protect long-term cardiovascular and bone health.
When to see a doctor
See a clinician for joint pain that lasts more than a few weeks, particularly if it involves multiple joints, is symmetrical (both hands, both feet), is accompanied by morning stiffness lasting longer than 30 minutes, or includes swelling and warmth in the joints. Persistent unexplained fatigue, low-grade fevers, or new rashes alongside joint symptoms also warrant evaluation. Early referral to a rheumatologist when autoimmune disease is suspected matters for long-term outcomes — the earlier disease-modifying therapy starts, the more joint function is preserved.
If you already have an autoimmune diagnosis, get in touch promptly with your specialist for new or worsening symptoms, signs of infection (fever, cough, urinary symptoms, or any unusual illness while on immune-suppressing therapy), unexpected weight loss, or new symptoms outside the usual pattern of your disease.
Frequently asked questions
Are these medications safe long-term?
Most are well-studied with decades of post-approval data. The main long-term concerns across DMARDs, biologics, and JAK inhibitors are increased infection risk, periodic blood test abnormalities, and — for JAK inhibitors specifically — small but real cardiovascular and cancer signals that have prompted updated prescribing guidance. The benchmark for “safe” is not zero risk; it is the risk-benefit balance against active disease, which causes joint destruction, disability, and substantially elevated cardiovascular risk on its own. For most people with moderate-to-severe RA, treatment’s downsides are far smaller than the disease’s.
Can I treat autoimmune disease with diet alone?
No — for confirmed disease, diet alone is not sufficient. Diet supports treatment and meaningfully improves quality of life, energy, and cardiovascular risk, but it does not stop the immune system from attacking joints, the gut, or other tissues at the level that DMARDs do. The internet is full of stories of people who claim to have “reversed” autoimmune disease with diet, but these are usually accounts of remission (which can also occur with DMARDs, with brief diet experiments coincidentally bridging it) or misdiagnoses. Disease-modifying medication remains the foundation; diet is genuinely useful alongside it.
Will I be on these medications forever?
Many people are, but not all. The current “treat to target” philosophy aims for sustained remission or low disease activity, and after that has been maintained for some time, careful tapering of medication may be possible — with the understanding that flares can occur and need to be addressed quickly. Stopping medication on your own without monitoring almost always leads to a flare and loss of progress, sometimes with new joint damage. The conversation about reducing or stopping is one to have with a rheumatologist when control has been excellent for a long stretch.
